Biotech Values

[DewDiligence]

Re: More detail on GTCB’s U.S. ATryn program:

The 17 patients in the U.S. trial's active arm will be pooled with the 14 patients from the European study whose review is now pending, giving an effective active arm of 31 patients.

What’s remarkable about this is that we already know that the 14-patient data from the European study were basically solid, and hence the U.S. ATryn trial will begin with almost half of the active-arm data already in good shape. Obviously, this improves the probability of a successful trial outcome.

Comments?